Starling Oncology (STLNW) Total Non-Current Liabilities (2020 - 2026)

Starling Oncology (STLNW) has reported Total Non-Current Liabilities for 7 consecutive years, with $192.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities rose 19.37% year-over-year to $192.3 million; the trailing twelve-month figure through Jun 2026 stood at $192.3 million (up 19.37% YoY), and the FY2025 full-year result was $167.8 million, down 0.57% from the prior year.
• Total Non-Current Liabilities climbed to $192.3 million in Q2 2026 per STLNW's latest filing, from $176.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $192.3 million in Q2 2026 and bottomed at $53.9 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $145.5 million across 5 years, with a median of $152.6 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities jumped 798.21% in 2022, then decreased 3.07% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $134.5 million in 2022, then increased by 10.85% to $149.1 million in 2023, then rose by 13.15% to $168.7 million in 2024, then declined by 0.57% to $167.8 million in 2025, then advanced by 14.62% to $192.3 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $192.3 million, $176.9 million, and $167.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.